Stephen Silberstein, AAN 2019 – Advances in the prevention and treatment of migraine
US Neurology Editorial Board member, Stephen Silberstein (Thomas Jefferson University, Philadelphia, USA), discusses the most significant advances in the prevention and treatment of migraine in the last year.
Questions
- What do you consider the most important developments in migraine prevention and treatment in the last year? (0:04)
- What is the rationale for the use of anti epileptic drugs (AEDs) in the prevention and treatment of migraine? (0:49)
- Which AEDs do you recommend in the prevention of migraine and which might play a role in the future? (1:39)
- What is your opinion on the use of cannabinoids in the treatment of migraine? (2:13)
- What are the most exciting therapies currently in development in the field of migraine prevention and treatment? (3:19)
- Please summarize your highlights so far at this AAN meeting. (3:35)
Speaker disclosures:
Scientific Advisory Boards: Abide Therapeutics; Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; Cefaly; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Health Holdings, LLC; eNeura Inc.; electroCore Medical, LLC; Lilly USA, LLC; Medscape, LLC; NINDS; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.
Editorial Boards: Cephalalgia; Current Pain and Headache Reports; CNS Drugs; Topics in Pain Management; and Neurology.
Consultancies: Allergan; Amgen; eNeura; ElectroCore Medical; Mitsubishi Tanabe; Medtronic; Neuralieve; Pfizer; Supernus; and Teva.
Speakers’ Bureaus: Amgen; Teva; and Supernus.
Research Support, Commercial Entities (Past 2 years): GlaxoSmithKline; Allergan; Merck; Novartis; NIH; Neurolieve; MAP; Endo Now: Amgen; ElectroCore; Avanir; Allergan; Teva; and Lilly.
Research Support, Government Entities: NIH.
Research Support, Foundations and Societies: AHS and IHS.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.